Staffan Widengren, director of corporate projects, at Recipharm spoke with EPM Magazine about the FMD regulation and what it means for the pharmaceutical sector. He also discusses the potential impact Brexit could have on the FMD and what it may mean for the UK market.
On Saturday 9th February 2019, the Falsified Medicines Directive (FMD) came into effect in order to prevent counterfeit drugs reaching patient possession. However, as Brexit uncertainty lingers, pharmaceutical manufacturers based in the UK remain unaware as to how the departure will impact their regulatory obligations.
When drug products are transferred from the UK to the EU market, they will still need to comply with FMD requirements.